Vol 7, Supplement 1 (February 11, 2018): Translational Lung Cancer Research

Editorial

An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs)

Santiago Viteri, Rafael Rosell

PDF Pages: S1-S4 Full Text (2191) Open Access

Treatment redirection from cure to palliation, then cure again? A cautious, but urgent matter

Jhingook Kim

PDF Pages: S5-S8 Full Text (1449) Open Access

Emerging resistance pathways in lung cancer: what has ROS-1 taught us?

Doraid Alrifai, Martin D. Forster, Sam M. Janes

PDF Pages: S9-S12 Full Text (1815) Open Access

Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer

Wan Ling Tan, Daniel S. W. Tan

PDF Pages: S13-S18 Full Text (1704) Open Access

PACIFIC trial: new perspectives for immunotherapy in lung cancer

Francesco Agustoni, Fred R. Hirsch

PDF Pages: S19-S24 Full Text (5796) Chinese (1205) Open Access

Can population data guide surveillance strategies for second primary lung cancers?

Andrew J. Arifin, Mark T. Corkum, Alexander V. Louie

PDF Pages: S25-S27 Full Text (1633) Open Access

Nivolumab as first-line treatment in non-small cell lung cancer patients—key factors: tumor mutation burden and PD-L1 ≥50%

Paul Zarogoulidis, Vasilis Papadopoulos, Elena Maragouli, George Papatsibas, Chrysanthi Sardeli, Yan-Gao Man, Chong Bai, Haidong Huang

PDF Pages: S28-S30 Full Text (3629) Open Access

Next-generation molecular therapy in lung cancer

Jun Qian, Pierre P. Massion

PDF Pages: S31-S34 Full Text (2589) Open Access

Putting the brakes on CTLA-4 inhibition in lung cancer?

Meghan J. Mooradian, Justin F. Gainor

PDF Pages: S35-S38 Full Text (2257) Open Access

Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?—the shifting paradigm of therapeutics

Malinda Itchins, Stephen Clarke, Nick Pavlakis

PDF Pages: S39-S45 Full Text (2428) Open Access

Tumor heterogenicity: multiple needle biopsies from different lesion sites—key to successful targeted therapy and immunotherapy

Paul Zarogoulidis, Vasilis Papadopoulos, Elena Maragouli, George Papatsibas, Ilias Karapantzos, Chong Bai, Haidong Huang

PDF Pages: S46-S48 Full Text (2081) Open Access

Long-term CT surveillance after primary lung cancer treatment captures events in all risk groups

John Kang, Amit K. Chowdhry, Michael T. Milano

PDF Pages: S49-S53 Full Text (1564) Open Access

The risk of second primary lung cancer: an unsolved dilemma

Antoinette J. Wozniak, Ann G. Schwartz

PDF Pages: S54-S56 Full Text (3692) Open Access

Editorial on PanCan study

Henry M. Marshall,, Ian A. Yang, Rayleen V. Bowman, Kwun M. Fong

PDF Pages: S57-S59 Full Text (1800) Open Access

Letter to the Editor

Response to “an innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)”

Nico van Zandwijk, Jennifer McDiarmid, Himanshu Brahmbhatt, Glen Reid

PDF Pages: S60-S61 Full Text (2007) Open Access

Meet the Professor

Prof. Lukas Bubendorf: the pros and cons of using cytology specimens in molecular testing

Brad Li, Vanessa Zhao

PDF Pages: S62-S63 Full Text (1451) Open Access

Prof. Nir Peled: CT first, biomarkers next

Brad Li, Lilian Xie

PDF Pages: S64-S66 Full Text (Video) (1837) Open Access

Dr. Lucio Crinò: our greatest challenge is finding the right treatment for the right patients

Brad Li, Bella Poon

PDF Pages: S67-S69 Full Text (Video) (1373) Open Access

Dr. David Ross Camidge: always be the first to see something

Brad Li, Maxine Feng

PDF Pages: S70-S71 Full Text (Video) (2150) Open Access

Dr. Jhingook Kim: surgeons are not merely technicians, but scientists

Brad Li

PDF Pages: S72-S73 Full Text (1082) Open Access

Dr. Vera Hirsh: improving patient’s quality of life is necessary for cancer treatment

Brad Li, Vicky Wong

PDF Pages: S74-S75 Full Text (Video) (1349) Open Access

Dr. Ignacio Gil-Bazo: family support is my key to success!

Brad Li, Vicky Wong

PDF Pages: S76-S77 Full Text (Video) (1421) Open Access

Professor Fred R. Hirsch, the IASLC CEO—showing you around the 18th World Conference on Lung Cancer (WCLC 2017)

Lynn Ma, Chao-Xiu(Melanie) He

PDF Pages: S78-S80 Full Text (Video) (1511) Open Access

Professor David Ball: prophylactic cranial irradiation (PCI) benefits patients with SCLC

Macy Liu

PDF Pages: S81-S82 Full Text (Video) (1582) Open Access

Professor Raymond U. Osarogiagbon: another major challenge over next decades—how to incorporate the cutting-edge diagnostics and biologic prognosticating ability into a traditionally anatomy-centered TNM staging system

Lynn Ma, Chao-Xiu(Melanie) He

PDF Pages: S83-S87 Full Text (Video) (1257) Open Access

Professor Fred R. Hirsch: together, our voices are much stronger than individually—a special interview about the 2017 Lung Cancer Awareness Month campaign

Chao-Xiu(Melanie) He

PDF Pages: S88-S90 Full Text (1294) Open Access

Disclosure:

The supplement was published without any sponsorship or funding.